Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00908
|
|||||
| Drug Name |
Eltrombopag
|
|||||
| Synonyms |
Eltrombopag; Revolade; Promacta; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; UNII-S56D65XJ9G; SB497115; Eltrombopag-Isomer; SB-497115; SB 497115; S56D65XJ9G; CHEMBL461101; 1807882-48-9; SB-497115-GR; Eltrombopag (SB-497115-GR); 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; NCGC00274067-01
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Idiopathic thrombocytopenic purpura [ICD11: 3B64.10] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H22N4O4
|
|||||
| Canonical SMILES |
CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
|
|||||
| InChI |
InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
|
|||||
| InChIKey |
SVOQIEJWJCQGDQ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 496775-61-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 442.5 | Topological Polar Surface Area | 115 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
5.4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:85010
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [3] | ||
| References | ||||||
| 1 | Eltrombopag was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51. | |||||
| 3 | Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.